Bioeksen

Bioeksen is a privately held, revenue-generating molecular diagnostics company based in Istanbul, Turkey. Founded by academic scientists, it has grown into a significant global exporter, having sold 200 million tests to 85 countries, particularly during the COVID-19 pandemic. The company's core innovation lies in its integrated system—combining proprietary sample prep (vNAT), qPCR kits (vCAP), and automation software (Sigmoida)—to simplify and accelerate lab workflows. With ISO-certified manufacturing capable of 2 million tests per day and WHO/FDA approvals, Bioeksen is positioned as a key player in making comprehensive diagnostics more accessible.

Integrated molecular diagnostics system combining proprietary sample preparation (vNAT), multiplex qPCR assay kits (vCAP), and automation/analysis software (Sigmoida) to streamline workflow from sample to result.

Bioeksen competes in the global molecular diagnostics market against giants like Roche, Abbott, Thermo Fisher, and Qiagen. Its competitive differentiation lies in its integrated system approach, high-multiplex panels, cost-effectiveness, and focus on accessibility for a broad range of laboratory settings.